Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Neurim Pharmaceuticals Ltd.
DescriptionSelective uncompetitive NMDA receptor modulator and MAO-B and GSK3 beta inhibitor
Molecular Target Monoamine oxidase B (MAO-B) ; Glycogen synthase kinase 3 beta (GSK3B)
Mechanism of ActionMonoamine oxidase B (MAO-B) inhibitor; Glycogen synthase kinase 3 (GSK3) beta inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today